pubmed-article:15814104 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:15814104 | lifeskim:mentions | umls-concept:C0031330 | lld:lifeskim |
pubmed-article:15814104 | lifeskim:mentions | umls-concept:C0034830 | lld:lifeskim |
pubmed-article:15814104 | lifeskim:mentions | umls-concept:C0486616 | lld:lifeskim |
pubmed-article:15814104 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
pubmed-article:15814104 | lifeskim:mentions | umls-concept:C1510438 | lld:lifeskim |
pubmed-article:15814104 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
pubmed-article:15814104 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
pubmed-article:15814104 | lifeskim:mentions | umls-concept:C1711351 | lld:lifeskim |
pubmed-article:15814104 | lifeskim:mentions | umls-concept:C0752283 | lld:lifeskim |
pubmed-article:15814104 | pubmed:issue | 5 | lld:pubmed |
pubmed-article:15814104 | pubmed:dateCreated | 2005-4-7 | lld:pubmed |
pubmed-article:15814104 | pubmed:abstractText | The subunit composition and pharmacology of alpha-Conotoxin MII-binding (alpha-CtxMII) nicotinic acetylcholine receptors (nAChR) was studied by an improved [(125)I]-alpha-CtxMII membrane binding method. This binding method facilitates pharmacological studies that have been difficult to accomplish with [(125)I]-alpha-CtxMII autoradiography or alpha-CtxMII inhibition of [(125)I]-epibatidine binding. Binding densities and K(d)-values obtained by this [(125)I]-alpha-CtxMII membrane binding were similar to the values obtained by autoradiography or alpha-CtxMII inhibition of [(125)I]-epibatidine binding, verifying that each of these approaches measures the same nAChR population. Binding results with nAChR subunit-null mutant mice confirm and extend observations from earlier studies: [(125)I]-alpha-CtxMII binding measures two sets of alpha6beta2* nAChR (alpha4alpha6beta2beta3 or alpha6beta2beta3). Most nicotinic agonists and antagonists show monophasic inhibition of [(125)I]-alpha-CtxMII binding, indicating that alpha4alpha6beta2beta3 and alpha6beta2beta3 have similar binding properties. Comparison of the binding and activation profiles of alpha6beta2* nAChR to those of other nAChR subtypes (alpha4beta2* and beta4*) indicates that these receptors have distinctly different pharmacology indicating that it may be possible to target alpha6beta2* nAChR selectively to develop compounds that might be therapeutically useful. | lld:pubmed |
pubmed-article:15814104 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15814104 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15814104 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15814104 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15814104 | pubmed:language | eng | lld:pubmed |
pubmed-article:15814104 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15814104 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:15814104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15814104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15814104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15814104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15814104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15814104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15814104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15814104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15814104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15814104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15814104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15814104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15814104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15814104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15814104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15814104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15814104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15814104 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15814104 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:15814104 | pubmed:month | Apr | lld:pubmed |
pubmed-article:15814104 | pubmed:issn | 0028-3908 | lld:pubmed |
pubmed-article:15814104 | pubmed:author | pubmed-author:McIntoshJ... | lld:pubmed |
pubmed-article:15814104 | pubmed:author | pubmed-author:CollinsAllan... | lld:pubmed |
pubmed-article:15814104 | pubmed:author | pubmed-author:MarksMichael... | lld:pubmed |
pubmed-article:15814104 | pubmed:author | pubmed-author:WhiteakerPaul... | lld:pubmed |
pubmed-article:15814104 | pubmed:author | pubmed-author:GradySharon... | lld:pubmed |
pubmed-article:15814104 | pubmed:author | pubmed-author:SalminenOutiO | lld:pubmed |
pubmed-article:15814104 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:15814104 | pubmed:volume | 48 | lld:pubmed |
pubmed-article:15814104 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:15814104 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:15814104 | pubmed:pagination | 696-705 | lld:pubmed |
pubmed-article:15814104 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:meshHeading | pubmed-meshheading:15814104... | lld:pubmed |
pubmed-article:15814104 | pubmed:year | 2005 | lld:pubmed |
pubmed-article:15814104 | pubmed:articleTitle | The subunit composition and pharmacology of alpha-Conotoxin MII-binding nicotinic acetylcholine receptors studied by a novel membrane-binding assay. | lld:pubmed |
pubmed-article:15814104 | pubmed:affiliation | Institute for Behavioral Genetics, University of Colorado, Boulder, 80309, USA. outi.salminen@helsinki.fi | lld:pubmed |
pubmed-article:15814104 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:15814104 | pubmed:publicationType | Comparative Study | lld:pubmed |
pubmed-article:15814104 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
pubmed-article:15814104 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
pubmed-article:15814104 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15814104 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15814104 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15814104 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15814104 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15814104 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15814104 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15814104 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15814104 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15814104 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15814104 | lld:pubmed |